Coronary microvascular dysfunction due to Chagas disease: where are we now?

References

• Bern C, Messenger LA, Whitman JD, et al. Chagas disease in the United States: a public health approach. Clin Microbiol Rev. 2019;33(1). DOI:10.1128/CMR.00023-19
   PubMed Web of Science ®Google Scholar
• Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1545–1602. DOI:10.1016/S0140-6736(16)31678-6
   PubMed Web of Science ®Google Scholar
• Monge-Maillo B, Lopez-Velez R. Challenges in the management of Chagas disease in Latin-American migrants in Europe. Clin Microbiol Infect. 2017;23(5):290–295.
   PubMed Web of Science ®Google Scholar
• Rassi A Jr., Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388–1402.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Rassi JA, Moraes OG, et al. Guideline of the Brazilian society of cardiology on diagnosis and treatment of patients with Chagas disease cardiomyopathy; 2022.
   Google Scholar
• Marin-Neto JA, Cunha-Neto E, Maciel BC, et al. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115(9):1109–1123.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Simoes MV, Rassi Junior A. Pathogenesis of chronic Chagas cardiomyopathy: the role of coronary microvascular derangements. Rev Soc Bras Med Trop. 2013;46(5):536–541.
   PubMed Web of Science ®Google Scholar
• VIANNA G. Contribuição para o estudo da anatomia patolojica da “Molestia de Carlos Chagas”: (Esquizotripanoze humana ou tireoidite parazitaria). Memórias Inst Oswaldo Cruz. 1911;3(2):276–294.
   Google Scholar
• Torres CM. Myocytolysis and fibrosis of the myocardium in Chagas’ disease. Mem Inst Oswaldo Cruz. 1960;58:161–182.
   PubMedGoogle Scholar
• Ferrans VJ, Milei J, Tomita Y, et al. Basement membrane thickening in cardiac myocytes and capillaries in chronic Chagas’ disease. Am J Cardiol. 1988;61(13):1137–1140.
   PubMed Web of Science ®Google Scholar
• Torres CM. Arteriosclerosis of the fine arterial branches of the myocardium (Chagas’ coronaritis) & focal myocytolysis in chronic Chagas’ heart disease. Hospital. 1958;54(5):597–610.
   PubMedGoogle Scholar
• Oliveira JS, Monteiro dos Santos, Muccillo G, et al. Increased capacity of the coronary arteries in chronic Chagas’ heart disease: further support for the neurogenic pathogenesis concept. Am Heart J. 1985;109(2):304–308.
   PubMed Web of Science ®Google Scholar
• OLIVEIRA JAMD. Heart aneurysm in Chagas’ disease. Rev Inst Med Trop São Paulo. 1998;40(5):301–307.
   PubMedGoogle Scholar
• Simoes MV, Marin GB, Antloga CM, et al. Tônus e diâmetro arterial coronário não se correlacionam com o grau de denervação autonômica em pacientes com cardiopatia chagásica crônica. Rev Bras Cardiol Invas. 2008;16(1):70–76.
   Google Scholar
• Oliveira JS, Mello De Oliveira JA, Frederigue U Jr., et al. Apical aneurysm of Chagas’s heart disease. Br Heart J. 1981;46(4):432–437.
   PubMedGoogle Scholar
• Ferreira CS, Lopes ER, Chapadeiro E, et al. Coronariografia post-morten na cardite chagásica crônica: correlação anátomo-radiológica. Coronariografia post-morten na cardite chagásica crônica: correlação anátomo-radiológica. Ann N Y Acad Sci. 1980;345:165–187.
   PubMedGoogle Scholar
• Tanowitz HB, Kaul DK, Chen B, et al. Compromised microcirculation in acute murine Trypanosoma cruzi infection. J Parasitol. 1996;82(1):124–130. DOI:10.2307/3284127
   PubMed Web of Science ®Google Scholar
• Torres FW, Acquatella H, Condado JA, et al. Coronary vascular reactivity is abnormal in patients with Chagas’ heart disease. Am Heart J. 1995;129(5):995–1001.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Simoes MV, Ayres-Neto EM, et al. Studies of the coronary circulation in Chagas’ heart disease. Sao Paulo Med J. 1995;113(2):826–834. DOI:10.1590/S1516-31801995000200014
   PubMedGoogle Scholar
• Morris SA, Tanowitz HB, Wittner M, et al. Pathophysiological insights into the cardiomyopathy of Chagas’ disease. Circulation. 1990;82(6):1900–1909.
   PubMed Web of Science ®Google Scholar
• Rossi MA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas’ disease. Am Heart J. 1990;120(1):233–236.
   PubMed Web of Science ®Google Scholar
• De Oliveira JA M. Observações sobre a histoquímica de algumas enzimas do miocárdio na fase crônica da infecção experimental pelo Trypanosoma cruzi, Chagas, 1909, em ratos Wistar. Rev Goiana Med. 1976;22:1–65.
   Google Scholar
• Rossi MA, Goncalves S, Ribeiro-dos-Santos R. Experimental Trypanosoma cruzi cardiomyopathy in BALB/c mice. The potential role of intravascular platelet aggregation in its genesis. Am J Pathol. 1984;114(2):209–216.
   PubMed Web of Science ®Google Scholar
• Rossi MA, Carobrez SG. Experimental Trypanosoma cruzi cardiomyopathy in BALB/c mice: histochemical evidence of hypoxic changes in the myocardium. Br J Exp Pathol. 1985;66(2):155–160.
   PubMedGoogle Scholar
• Factor SM, Cho S, Wittner M, et al. Abnormalities of the coronary microcirculation in acute murine Chagas’ disease. Am J Trop Med Hyg. 1985;34(2):246–253.
   PubMed Web of Science ®Google Scholar
• Andrade ZA, Andrade SG, Correa R, et al. Myocardial changes in acute Trypanosoma cruzi infection. Ultrastructural evidence of immune damage and the role of microangiopathy. Am J Pathol. 1994;144(6):1403–1411.
   PubMed Web of Science ®Google Scholar
• Morris SA, Tanowitz H, Makman M, et al. Trypanosoma cruzi: alteration of cAMP metabolism following infection of human endothelial cells. Exp Parasitol. 1992;74(1):69–76.
   PubMed Web of Science ®Google Scholar
• Libby P, Alroy J, Pereira ME. A neuraminidase from Trypanosoma cruzi removes sialic acid from the surface of mammalian myocardial and endothelial cells. J Clin Invest. 1986;77(1):127–135.
   PubMed Web of Science ®Google Scholar
• Tanowitz HB, Burns ER, Sinha AK, et al. Enhanced platelet adherence and aggregation in Chagas’ disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg. 1990;43(3):274–281. DOI:10.4269/ajtmh.1990.43.274
   PubMed Web of Science ®Google Scholar
• Molina-Berrios A, Campos-Estrada C, Lapier M, et al. Protection of vascular endothelium by aspirin in a murine model of chronic Chagas’ disease. Parasitol Res. 2013;112(7):2731–2739. DOI:10.1007/s00436-013-3444-x
   PubMed Web of Science ®Google Scholar
• Molina-Berrios A, Campos-Estrada C, Henriquez N, et al. Protective role of acetylsalicylic acid in experimental Trypanosoma cruzi infection: evidence of a 15-epi-lipoxin A(4)-mediated effect. PLoS Negl Trop Dis. 2013;7(4):e2173. DOI:10.1371/journal.pntd.0002173
   PubMed Web of Science ®Google Scholar
• Huang H, Calderon TM, Berman JW, et al. Infection of endothelial cells with Trypanosoma cruzi activates NF-kappaB and induces vascular adhesion molecule expression. Infect Immun. 1999;67(10):5434–5440. DOI:10.1128/IAI.67.10.5434-5440.1999
   PubMed Web of Science ®Google Scholar
• Morris SA, Weiss LM, Factor S, et al. Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice. J Am Coll Cardiol. 1989;14(3):782–789.
   PubMed Web of Science ®Google Scholar
• Ferreira V, Molina MC, Schwaeble W, et al. Does Trypanosoma cruzi calreticulin modulate the complement system and angiogenesis? Trends Parasitol. 2005;21(4):169–174.
   PubMed Web of Science ®Google Scholar
• Feit A, El-Sherif N, Korostoff S. Chagas’ disease masquerading as coronary artery disease. Arch Intern Med. 1983;143(1):144–145.
   PubMedGoogle Scholar
• Simoes MV, Ayres EM, Santos JL, et al. Detection of myocardial ischemia in chronic Chagas disease patients with atypic precordial pain by exercise and Holter tests. Arq Bras Cardiol. 1993;60(5):315–319.
   PubMedGoogle Scholar
• Laranja FS, Dias E, Miranda A, et al. Chagas’ disease; a clinical, epidemiologic, and pathologic study. Circulation. 1956;14(6):1035–1060.
   PubMed Web of Science ®Google Scholar
• Hammermeister KE, Caeiro T, Crespo E, et al. Left ventricular wall motion in patients with Chagas’s disease. Br Heart J. 1984;51(1):70–76.
   PubMedGoogle Scholar
• Simoes MV, Pintya AO, Bromberg-Marin G, et al. Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas’ cardiomyopathy. Am J Cardiol. 2000;86(9):975–981. DOI:10.1016/S0002-9149(00)01133-4
   PubMed Web of Science ®Google Scholar
• Hiss FC, Lascala TF, Maciel BC, et al. Changes in myocardial perfusion correlate with deterioration of left ventricular systolic function in chronic Chagas’ cardiomyopathy. JACC Cardiovasc Imaging. 2009;2(2):164–172.
   PubMed Web of Science ®Google Scholar
• Vianna LG, Campos GP, de Magalhaes AV. Myocardial infarct without coronary obstruction associated with chronic Chagas cardiopathy. Arq Bras Cardiol. 1979;33(1):41–47.
   PubMedGoogle Scholar
• Kuschnir E, Kustich F, Epelman M, et al. Valoration de fluxo miocardico con Rb 86, en pacientes con cardiopatia chagasica, con insuficiencia coronaria y en controles normales. Arq Bras Cardiol. 1974;27(1):187–196.
   Google Scholar
• Kuschnir E, Kustich F, Epelman M, et al. Valoration de fluxo miocardico con Rb 86, en pacientes con cardiopatia chagasica, con insuficiencia coronaria y en controles normales. Parte 2 Respuesta al ejercicio y a la cardiotonificación aguda. Arq Bras Cardiol. 1974;27:721–732.
   Google Scholar
• Castro R, Kuschnir E, S H. Evaluacion de la performance cardíaca y perfusion miocárdica com radiotrazadores en la cardiopatia chagásica crônica. Rev Fed Arg Cardiol. 1988;17:226–231.
   Google Scholar
• Hagar JM, Rahimtoola SH. Chagas’ heart disease in the United States. N Engl J Med. 1991;325(11):763–768.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Marzullo P, Marcassa C, et al. Myocardial perfusion abnormalities in chronic Chagas’ disease as detected by thallium-201 scintigraphy. Am J Cardiol. 1992;69(8):780–784. DOI:10.1016/0002-9149(92)90505-S
   PubMed Web of Science ®Google Scholar
• Sarabanda AV, Sosa E, Simoes MV, et al. Ventricular tachycardia in Chagas’ disease: a comparison of clinical, angiographic, electrophysiologic and myocardial perfusion disturbances between patients presenting with either sustained or nonsustained forms. Int J Cardiol. 2005;102(1):9–19.
   PubMed Web of Science ®Google Scholar
• Marin Neto JA, Marzulo P, Ayres-Neto E, et al. Myocardial perfusion disturbances detected by Tc-99m microsphere scintigraphy in chagas’ patients with angiographicaly normal coronary arteries. Circulation. 1995;92:2250.
   Google Scholar
• Abuhid IM, Pedroso ER, Rezende NA. Scintigraphy for the detection of myocardial damage in the indeterminate form of Chagas disease. Arq Bras Cardiol. 2010;95(1):30–34.
   PubMed Web of Science ®Google Scholar
• Peix A, Garcia R, Sanchez J, et al. Myocardial perfusion imaging and cardiac involvement in the indeterminate phase of Chagas disease. Arq Bras Cardiol. 2013;100(2):114–119. DOI:10.5935/abc.20130023
   PubMed Web of Science ®Google Scholar
• Rabelo DR, Rocha MOC, de Barros MVL, et al. Impaired coronary flow reserve in patients with indeterminate form of Chagas’ disease. Echocardiography. 2014;31(1):67–73.
   PubMed Web of Science ®Google Scholar
• Kuschnir E, Sgammini H, Castro R, et al. Chronic Chagas’ cardiomyopathy: effects of dipyradamole on ventricular dynamics. Arq Bras Cardiol. 1983;41(5):373–378.
   PubMedGoogle Scholar
• Noya-Rabelo MM, Macedo CT, Larocca T, et al. The presence and extension of myocardial fibrosis in the undetermined form of Chagas’ disease: a Study using magnetic resonance. Arq Bras Cardiol. 2018;110(2):124–131. DOI:10.5935/abc.20180016
   PubMed Web of Science ®Google Scholar
• Marin-Neto J, Souza A, Maciel B, et al. Avaliação angiocardiográfica nuclear do efeito do dinitrato de isosorbitol em pacientes chagásicos. Arq Bras Cardiol. 1988;51:367–371.
   PubMedGoogle Scholar
• Pavao RB, Moreira HT, Pintya AO, et al. Aspirin plus verapamil relieves angina and perfusion abnormalities in patients with coronary microvascular dysfunction and Chagas disease: a pilot non-randomized study. Rev Soc Bras Med Trop. 2021;54(0181):1–9. DOI:10.1590/0037-8682-0181-2021
   Google Scholar
• Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol. 2005;46(8):1553–1558. DOI:10.1016/j.jacc.2005.06.067
   PubMed Web of Science ®Google Scholar
• Regueiro A, Garcia-Alvarez A, Sitges M, et al. Myocardial involvement in Chagas disease: insights from cardiac magnetic resonance. Int J Cardiol. 2013;165(1):107–112. DOI:10.1016/j.ijcard.2011.07.089
   PubMed Web of Science ®Google Scholar
• Sotgia B, Sciagra R, Olivotto I, et al. Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med. 2008;49(7):1090–1096. DOI:10.2967/jnumed.107.050138
   PubMed Web of Science ®Google Scholar
• Wang L, Yan C, Zhao S, et al. Comparison of (99m)Tc-MIBI SPECT/18F-FDG PET imaging and cardiac magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy: assessment of cardiac function and myocardial injury. Clin Nucl Med. 2012;37(12):1163–1169.
   PubMed Web of Science ®Google Scholar
• Barizon GC, Simoes MV, Schmidt A, et al. Relationship between microvascular changes, autonomic denervation, and myocardial fibrosis in Chagas cardiomyopathy: evaluation by MRI and SPECT imaging. J Nucl Cardiol. 2020;27(2):434–444.
   PubMed Web of Science ®Google Scholar
• Campos FA, Magalhaes ML, Moreira HT, et al. Chagas cardiomyopathy as the etiology of suspected coronary microvascular disease. A comparison study with suspected coronary microvascular disease of other etiologies. Arq Bras Cardiol. 2020;115(6):1094–1101. DOI:10.36660/abc.20200381
   PubMed Web of Science ®Google Scholar
• Tanaka DM, de Oliveira LFL, Marin-Neto JA, et al. Prolonged dipyridamole administration reduces myocardial perfusion defects in experimental chronic Chagas cardiomyopathy. J Nucl Cardiol. 2019;26(5):1569–1579. DOI:10.1007/s12350-018-1198-7
   PubMed Web of Science ®Google Scholar
• de Oliveira LF L, Thackeray JT, Marin Neto JA, et al. Regional myocardial perfusion disturbance in experimental chronic Chagas cardiomyopathy. J Nucl Med. 2018;59(9):1430–1436. DOI:10.2967/jnumed.117.205450
   PubMed Web of Science ®Google Scholar
• Oliveira LFL, Romano MMD, Carvalho EEV, et al. Histopathological correlates of global and segmental left ventricular systolic dysfunction in experimental chronic Chagas cardiomyopathy. J Am Heart Assoc. 2016;5(1).
   PubMed Web of Science ®Google Scholar
• Pereira IR, Vilar-Pereira G, Moreira OC, et al. Pentoxifylline reverses chronic experimental Chagasic cardiomyopathy in association with repositioning of abnormal CD8+ T-cell response. PLoS Negl Trop Dis. 2015;9(3):e0003659. DOI:10.1371/journal.pntd.0003659
   PubMed Web of Science ®Google Scholar
• Tanaka D, Fabricio C, Marin-Neto J, et al. Prolonged use of pentoxifylline prevents progression of myocardial perfusion disturbance and reduces inflammation in the hamster experimental model of chronic Chagas cardiomyopathy. Eur J Heart Fail. 2020;22:54.
   PubMed Web of Science ®Google Scholar